Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909470 | 0.77 | — | — | |
| SCHEMBL15022961 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL7309579 | 0.75 | — | — | |
| SCHEMBL3082239 | 0.71 | EPHX2 (0.60) | — | |
| SCHEMBL3072038 | 0.71 | EPHX2 (0.33) | — | |
| SCHEMBL24940204 | 0.71 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3079023 | 0.71 | EPHX2 (0.43) | — | |
| SCHEMBL3071718 | 0.71 | EPHX2 (0.43) | — | |
| SCHEMBL10012499 | 0.71 | — | — | |
| SCHEMBL3068816 | 0.71 | EPHX2 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11687003-B2 | Negative resist pattern-forming method, and composition for upper layer film formation | JSR CORPORATION (JP) | 2023-06-27 | — | — | US | disclosed |
| US-20190004426-A1 | NEGATIVE RESIST PATTERN-FORMING METHOD, AND COMPOSITION FOR UPPER LAYER FILM FORMATION | JSR CORPORATION (JP) | 2019-01-03 | — | — | US | disclosed |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| US-10073344-B2 | Negative resist pattern-forming method, and composition for upper layer film formation | JSR CORPORATION (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20160299432-A1 | NEGATIVE RESIST PATTERN-FORMING METHOD, AND COMPOSITION FOR UPPER LAYER FILM FORMATION | JSR CORPORATION (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| US-8957212-B2 | Photobase generator | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2368875-B1 | PHOTOBASE GENERATOR | WAKO PURE CHEM IND LTD (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8198487-B2 | Method for lithium exchange reactions | LONZA AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20110233048-A1 | PHOTOBASE GENERATOR | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2368875-A1 | PHOTOBASE GENERATOR | Wako Pure Chemical Industries, Ltd. (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| EP-2109616-B1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20100113839-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2109616-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008095646-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110233048-A1 | PHOTOBASE GENERATOR | CYBA, CRY1, GNB1 | GRIN2D 2293/4885GRIN3B 1831/4885GRIN1 1294/4885 |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | GRIN2D 4092/4885GRIN3B 3525/4885GRIN1 2003/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | GRIN2D 4092/4885GRIN3B 3525/4885GRIN1 2003/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | GRIN2D 1925/4885GRIN3B 391/4885GRIN1 910/4885 |
| US-20100113839-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | SLC6A5, SLC6A9, SLC6A6 | GRIN2D 725/4885GRIN3B 311/4885GRIN1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.